article thumbnail

SGLT-2 inhibitor, cardiovascular risk and outcome in patients with comorbidity of hypertension and diabetes [Cardiovascular disease]

Annals of Family Medicine

Sodium-glucose transporter 2 (SGLT-2) inhibitors have been proved to decrease the cardiovascular adverse events in several large randomized controlled trials (RCTS), but evidence limited to patients with type 2 diabetes and ASCVD. Setting or Dataset Five electronic systems of community clinic.

article thumbnail

Biomarker Panel Improves Prediction of CKD Progression in Children

Physician's Weekly

Biomarkers were measured in stored plasma and urine collected five months after enrollment, and a regression tree-based model was constructed using a panel of clinically relevant biomarkers to predict the time to the composite event. A total of 599 children were included; 205 (34 percent) reached the primary outcome of CKD progression.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Dupixent for Bullous Pemphigoid

Physician's Weekly

Patients with moderate-to-severe bullous pemphigoid were randomly assigned to receive Dupixent 300 mg (53 individuals) or placebo (53 individuals) added to standard-of-care oral corticosteroids. percent of patients treated with Dupixent achieved clinically meaningful itch reduction versus 10.5 At 36 weeks, 18.3 Additionally, 38.3

article thumbnail

Discontinuation versus continuation of statins: a systematic review [Cardiovascular disease]

Annals of Family Medicine

Objective: To examine the impact of discontinuation of statins compared to continuation on clinical outcomes. Population Studied: Adults ≥18 years Intervention/Instrument: Discontinuation of statin medications Outcome Measures: All-cause mortality, cardiovascular (CV) mortality, and CV events (e.g., stroke and MI).

Screening 130
article thumbnail

Comparing Oxygen Delivery Methods Before Intubation

Physician's Weekly

Outcomes assessed included hypoxemia during intubation, first-attempt during intubation success, serious adverse events (AEs), and all-cause mortality. Summary-level data were manually extracted using a structured data collection form. A frequent random-effects network meta-analysis was performed.

article thumbnail

Weekly LYN-005 Provides Sustained Risperidone Release in Schizophrenia

Physician's Weekly

from the New York Medical College School of Medicine in Valhalla, and colleagues conducted an open-label, nonrandomized, phase 3 trial involving clinically stable participants with schizophrenia or schizoaffective disorder. Leslie Citrome, M.D., for C min at week 1 and 1.04, 0.84, and 1.03

article thumbnail

Exploring the educational needs and preferences of physicians in pharmacogenomics in primary care practice [Education and training]

Annals of Family Medicine

Context Ten percent of patients using prescription drugs experience adverse drug events (ADE). A proportion of these ADEs can be explained by a difference in enzyme activity between individuals. Intra-individual variation in genetic composition is one of the key contributing factors determining enzyme activity.